These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19578355)

  • 21. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017.
    Carlsson SV; Roobol MJ
    Curr Opin Urol; 2017 May; 27(3):198-204. PubMed ID: 28221219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?
    Schmid M; Trinh QD; Graefen M; Fisch M; Chun FK; Hansen J
    World J Urol; 2014 Aug; 32(4):871-80. PubMed ID: 24825472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
    Steuber T; Vickers A; Haese A; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
    Int J Cancer; 2007 Apr; 120(7):1499-504. PubMed ID: 17205511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.
    Nam RK; Diamandis EP; Toi A; Trachtenberg J; Magklara A; Scorilas A; Papnastasiou PA; Jewett MA; Narod SA
    J Clin Oncol; 2000 Mar; 18(5):1036-42. PubMed ID: 10694554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patented prostate cancer biomarkers.
    Murphy L; Watson RW
    Nat Rev Urol; 2012 Aug; 9(8):464-72. PubMed ID: 22750955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer.
    Agarwal M; He C; Siddiqui J; Wei JT; Macoska JA
    Prostate; 2013 May; 73(6):573-81. PubMed ID: 23059958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
    Vickers A; Vertosick EA; Sjoberg DD; Hamdy F; Neal D; Bjartell A; Hugosson J; Donovan JL; Villers A; Zappala S; Lilja H
    J Urol; 2018 Jun; 199(6):1470-1474. PubMed ID: 29366640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment.
    Moradi A; Srinivasan S; Clements J; Batra J
    Cancer Metastasis Rev; 2019 Sep; 38(3):333-346. PubMed ID: 31659564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen and other serum and urine markers in prostate cancer.
    Stephan C; Ralla B; Jung K
    Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
    Vickers AJ; Ulmert D; Serio AM; Björk T; Scardino PT; Eastham JA; Berglund G; Lilja H
    Int J Cancer; 2007 Nov; 121(10):2212-7. PubMed ID: 17657743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
    Vickers A; Cronin A; Roobol M; Savage C; Peltola M; Pettersson K; Scardino PT; Schröder F; Lilja H
    J Clin Oncol; 2010 May; 28(15):2493-8. PubMed ID: 20421547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
    Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
    Bachour DM; Chahin E; Al-Fahoum S
    Asian Pac J Cancer Prev; 2015; 16(16):7085-8. PubMed ID: 26514494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that the PHI consistently outperforms PSA across diverse populations.
    Loeb S
    BJU Int; 2015 Apr; 115(4):500. PubMed ID: 25808708
    [No Abstract]   [Full Text] [Related]  

  • 38. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity.
    Finlay JA; Evans CL; Day JR; Payne JK; Mikolajczyk SD; Millar LS; Kuus-Reichel K; Wolfert RL; Rittenhouse HG
    Urology; 1998 May; 51(5):804-9. PubMed ID: 9610595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Biological markers of prostate cancer].
    Seitz C; Djavan B
    Ann Urol (Paris); 2006 Dec; 40(6):329-35. PubMed ID: 17214230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of sensitive immunoassays for free and total human glandular kallikrein 2.
    Väisänen V; Eriksson S; Ivaska KK; Lilja H; Nurmi M; Pettersson K
    Clin Chem; 2004 Sep; 50(9):1607-17. PubMed ID: 15247158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.